GlaxoSmithKline PakistanKAR:GLAXO +2.66%94 PS Ratio is 1.83 as of Jul. 05, 2026, which is 24% above its 10-year median of 1.47. GuruFocus rates KAR:GLAXO with a GF Score™ of 94/100 and a GF Value™ of ₨324.17 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 949 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks better than 57.74% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, GlaxoSmithKline Pakistan's share price is ₨387.01.
GlaxoSmithKline Pakistan's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₨211.50. Hence, GlaxoSmithKline Pakistan's PS Ratio for today is 1.83.
The historical rank and industry rank for GlaxoSmithKline Pakistan's PS Ratio or its related term are showing as below:
KAR:GLAXO'
s PS Ratio Range Over the Past 10 Years
Min: 0.47 Med: 1.47 Max: 3.05
Current: 1.83
During the past 13 years, GlaxoSmithKline Pakistan's highest PS Ratio was 3.05. The lowest was 0.47. And the median was 1.47.
KAR:GLAXO's PS Ratio is ranked better than 57.74% of 949
companies
in the Drug Manufacturers industry
Industry Median: 2.31
vs KAR:GLAXO: 1.83
GlaxoSmithKline Pakistan Ltd has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of GlaxoSmithKline Pakistan was 10.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 16.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 14.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 9.50% per year.
During the past 13 years, GlaxoSmithKline Pakistan's highest 3-Year average Revenue per Share Growth Rate was 18.60% per year. The lowest was 1.60% per year. And the median was 6.60% per year.
Back to Basics: PS Ratio
GlaxoSmithKline Pakistan (KAR:GLAXO) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's PS Ratio distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
GlaxoSmithKline Pakistan's Share Price of today is ₨387.01. GlaxoSmithKline Pakistan's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨211.50.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
GlaxoSmithKline Pakistan (KAR:GLAXO) has a PS Ratio of 1.83 as of Jul. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on GlaxoSmithKline Pakistan and its competitors. This is 24% above median its historical median of 1.47. Over the past decade, GlaxoSmithKline Pakistan's PS Ratio has ranged from 0.47 to 3.05. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #401 out of 949 companies in the Drug Manufacturers industry, placing it in the top 42.3%.
Is GlaxoSmithKline Pakistan's PS Ratio too high?
GlaxoSmithKline Pakistan's current PS Ratio of 1.83 is 24% above median its 10-year median of 1.47. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 3.05. The Drug Manufacturers industry median PS Ratio is 2.31. GlaxoSmithKline Pakistan's value of 1.83 is 20.8% below this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #401 out of 949 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #401 out of 949 companies for PS Ratio. This puts GlaxoSmithKline Pakistan in the upper half of its industry. The industry median PS Ratio is 2.31. GlaxoSmithKline Pakistan's value of 1.83 is 20.8% below this benchmark. Historically, GlaxoSmithKline Pakistan's own PS Ratio has ranged from 0.47 to 3.05 over the past decade. While the company's 10-year median is 1.47 vs. the industry median of 2.31, GlaxoSmithKline Pakistan has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.31, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current PS Ratio of 1.83 is 20.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current PS Ratio is 1.83, which is 24% above median its own 10-year median of 1.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.17, compared to a current price of ₨387.01 — trading 19.4% above its estimated fair value. The current PS Ratio is 1.83, which is 24% above median its 10-year median of 1.47 and 20.8% below the Drug Manufacturers industry median of 2.31. GlaxoSmithKline Pakistan's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current PS Ratio is 1.83 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨387.01 is trading 19.4% above its estimated GF Value™ of ₨324.17.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:GLAXO:
PS Ratio: 1.83 (24% above median its 10-year median of 1.47)
GF Value™: ₨324.17 vs. price of ₨387.01 (19.4% above fair value)
Industry Position: 20.8% below the Drug Manufacturers median (#401 of 949)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
94GF Score
Get the complete analysis for KAR:GLAXO
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
